Compare AbCellera Biologics Inc (ABCL) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ProShares UltraPro S&P500 — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while ProShares UltraPro S&P500 trades at $139.94. Which is the better fit depends on your goals.
| ABCL | UPRO | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $150.93 |
52-Week Low | $2.78 | $89.29 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
UPRO, the ProShares UltraPro S&P 500 ETF, trades at $144.41, up 2.64% with a bullish technical outlook from moving averages. The leveraged ETF faces neutral sentiment from oscillators while tracking S&P 500 performance. Recent news highlights sector rotation from tech stocks and mixed analyst views on S&P 500 targets ranging from 8,000 to 8,800 by year-end 2026.
The leveraged structure amplifies both gains and losses, making UPRO suitable for short-term trading amid expected S&P 500 volatility. Key risks include Fed policy uncertainty and sector rotation pressures, while opportunities exist if the S&P 500 reaches analyst targets. Earnings season performance and AI sector momentum remain critical catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
